Background: Automatic continuous positive airway pressure (automatic CPAP, APAP) is an effective treatment option in the obstructive sleep apnoea syndrome (OSAS). The differentiation of obstructive and central respiratory events is crucial in adjusting the optimal pressure in this treatment mode. In this pilot study we evaluated a new automatic CPAP algorithm in OSAS patients.
Methods: 14 patients with newly diagnosed obstructive sleep apnoea syndrome were enrolled. After a diagnostic polysomnography, patients were treated for one night with a new APAP device based on flow, snoring, relative minute volume and the obstructive pressure peak signal.
Results: The total apnoea/hypopnoea index (AHI) was 30.0 +/- 21.4/h at baseline and 3.7 +/- 5.3/h with APAP ( P < 0.005). Both obstructive AHI (22.7 +/- 20.5/h at baseline, 1.5 +/- 3.5/h with APAP, P < 0.005) and central AHI (7.3 +/- 4.9/h and 2.2 +/- 2.5/h, respectively, P < 0.01) as well as the arousal index (25.4 +/- 18.1/h and 5.1 +/- 3.8/h, respectively, P < 0.005) were reduced significantly with the new algorithm.
Conclusions: The new algorithm of an automatic CPAP device is effective in the treatment of obstructive sleep apnoea syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0028-1119519 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Alternative In-Home Protocol to Diagnose and Treat Obstructive Sleep Apnea.
Sleep Sci
December 2024
Sleep and Heart Laboratory, Pronto Socorro Cardiológico Universitário de Pernambuco (PROCAPE), Universidade de Pernambuco, Recife, PE, Brazil.
Obstructive sleep apnea (OSA) is a major public health problem of pandemic proportions. In-laboratory OSA diagnosis and continuous positive airway pressure (CPAP) titration are insufficient, considering the number of patients affected. Finding alternative ways to diagnose and treat OSA is mandatory, especially in this era of the coronavirus disease 2019 (COVID-19) pandemic.
View Article and Find Full Text PDFComparative effectiveness of therapies for sleep-disordered breathing in heart failure patients: A comprehensive systematic review and network meta-analysis.
Respir Med
January 2025
Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, 107 Yanjiang West Road, Guangzhou, 510120, China. Electronic address:
Background: The prevalence of sleep-disordered breathing (SDB) in patients with heart failure (HF) is a significant concern, leading to adverse outcomes. This network meta-analysis (NMA) is dedicated to evaluate the relative effectiveness of diverse therapeutic approaches for SDB treatments in the context of HF.
Methods: An extensive search up to May 19, 2023, was implemented in PubMed, Cochrane, Embase, and Web of Science to identify randomized controlled trials (RCTs).
Adherence to long-term non-invasive positive airway pressure therapy.
Dan Med J
October 2024
Respiratory Center East, Department of Anaesthesia, Pain, and Respiratory Support, Copenhagen University Hospital - Rigshospitalet - Glostrup.
Introduction: Studies have shown varying patient adherence to long-term non-invasive positive airway pressure therapy (nPAP). We aimed to investigate adherence to long-term nPAP in a Danish cohort of patients with chronic respiratory insufficiency and/or sleep-disordered breathing (SDB) due to neuromuscular disorders (NMD), obesity-hypoventilation syndrome (OHS) or other reasons.
Methods: This cohort study included all adult patients with association to the Respiratory Center East treated with long-term nPAP: bilevel (BiPAP), automatic (APAP) and continuous (CPAP) or adaptive servo-ventilation (ASV) with a remote monitoring system in April 2022.
Design, manufacture, and control of a low-cost positive airway pressure device.
HardwareX
September 2024
Department of Mechanical Engineering, University of Canterbury, Christchurch, New Zealand.
Current positive airway pressure devices cost NZ$800-$2500, posing a financial barrier for the estimated 1 billion individuals worldwide with sleep apnea and those researching respiratory diseases. Increasing diagnoses and research interest in the area necessitate a low-cost, easily accessible alternative. Thus, the mePAP, a high-quality, multipurpose, low-cost (∼NZ$250) positive airway pressure device, was designed and prototyped specifically for respiratory disease research, particularly for sleep apnea.
View Article and Find Full Text PDFFormulas to predict continuous positive airway pressure level using a home auto-adjusting device for obstructive sleep apnea treatment.
Sleep Breath
October 2024
Head of Pneumonology, Hospital Alemán, Buenos Aires, Argentina.
Article Synopsis
- The study aimed to create predictive equations for determining therapeutic continuous positive airway pressure (CPAP) based on home titration methods, factoring in the type of mask used.
- A total of 702 adult patients with obstructive sleep apnea were analyzed, and two models (M1 and M2) were developed to estimate CPAP requirements; M1 showed higher accuracy than M2.
- The results indicated that M1 had an error margin of ±3.2 cm HO, allowing 79% of patients to start using CPAP with reasonable accuracy compared to 64% for M2.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!